A Short ERK5 Isoform Modulates Nucleocytoplasmic Shuttling of Active ERK5 and Associates with Poor Survival in Breast Cancer

Author(s): Mariska Miranda, Jodi M. Saunus, Seçkin Akgül, Mahdi Moradi Marjaneh, Jamie R. Kutasovic, Wei Shi, Oishee Chatterjee, Francesco Casciello, Esdy Rozali, Herlina Y. Handoko, Adrian P. Wiegmans, Tianqing Liu, Jason S. Lee, Bryan W. Day, Stacey L. Edwards, Juliet D. French, Amy E. McCart Reed, Georgia Chenevix-Trench, Kum Kum Khanna, Peter T. Simpson, Sunil R. Lakhani and Fares Al-Ejeh

The nucleocytoplasmic shuttling of ERK5 has gained recent attention as a regulator of its diverse roles in cancer progression but the exact mechanisms for this shuttling are still under investigation. Using in vitro, in vivo and in silico studies, we investigated here the roles of shorter ERK5 isoforms in regulating the nucleocytoplasmic shuttling of active phosphorylated-ERK5 (pERK5). Retrospective cohorts of primary and metastatic breast cancer cases were used to evaluate the association of the subcellular localization of pERK5 with clinicopathological features. Extranuclear localization of pERK5 was observed during cell migration in vitro and at the invasive fronts of metastatic tumors in vivo. The nuclear and extranuclear cell fractions contained different isoforms of pERK5, which are encoded by splice variants expressed in breast and other cancers in the TCGA data. One isoform, isoform-3, lacks the C-terminal transcriptional domain and the nuclear localization signal. The co-expression of isoform-3 and full-length ERK5 associated with high epithelial-to-mesenchymal transition (EMT) and poor patient survival. Experimentally, expressing isoform-3 with full-length ERK5 in breast cancer cells increased cell migration, drove EMT and led to tamoxifen resistance. In breast cancer patient samples, pERK5 showed variable subcellular localizations where its extranuclear localization associated with aggressive clinicopathological features, metastasis, and poor survival. Our studies support a model of ERK5 nucleocytoplasmic shuttling driven by splice variants in an interplay between mesenchymal and epithelial states during metastasis. Using ERK5 as a biomarker and a therapeutic target should account for its splicing and context-dependent biological functions.